Eligibility for and Prescription of Urate-Lowering Treatment in Patients With Incident Gout in England
Author(s) -
ChangFu Kuo,
Matthew J. Grainge,
Christian Mallen,
Weiya Zhang,
Michael Doherty
Publication year - 2014
Publication title -
jama
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.688
H-Index - 680
eISSN - 1538-3598
pISSN - 0098-7484
DOI - 10.1001/jama.2014.14484
Subject(s) - gout , medicine , hyperuricemia , medical prescription , concomitant , uric acid , intensive care medicine , pharmacology
Gout is caused by urate crystal deposition secondary to persistent hyperuricemia. Current guidelines recommend urate-lowering treatment to prevent crystal deposition and encourage crystal dissolution for patients with more severe gout or concomitant conditions.1,2 However, after the first diagnosis, it remains unclear when such treatment is appropriate. We investigated the timing of eligibility for and prescription of urate-lowering treatment following first gout diagnosis and factors associated with prescription
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom